Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · cooperative agreement (b)
Sbir Phase Ii: an Advanced Web Portal for Artificial Intelligence (ai)-based Comprehensive Discovery of Repositioning Drugs -the Broader Impact of This Small Business Innovation Research (SBIR) Phase Ii Project Lies in Advancing the Development of Catos-ai (cancer Treatment Optimization Solutions ? Artificial Intelligence) Towards Integration With Healthcare-it Systems, Paving the Way for Commercialization After Completing Key Milestones in the Phase I Project. by Leveraging a Strong Collaboration Between Academia and Industry Experts, This Project Aims to Enhance the Global Competitiveness of This Innovative Technology, Addressing a Critical Need in Precision Oncology. the Anticipated Outcomes Include Substantial Improvements in Personalized Cancer Care and Accelerated Development of New Drug Options, Leading to Better Survival Rates for Cancer Patients While Reducing Time and Costs. Additionally, the Software Is Expected to Benefit Millions of Cancer Patients by Improving the Quality of Care, Supporting Pharmaceutical Research and Development, and Alleviating the Overall Healthcare Burden. This Small Business Innovation Research (SBIR) Phase Ii Project Aims to Build a Powerful Artificial Intelligence (AI) Based Clinical Decision-making Tool Called Catos-ai (cancer Treatment Optimization Solutions ? Artificial Intelligence) for Personalized Cancer Care. Addressing the Need for Advanced Ai Solutions in Precision Oncology and Drug Repositioning, the Project Will Utilize Machine Learning and Multi-omics Analysis to Discover New Drugs or Repurpose Existing Ones for Treating Non-small Cell Lung Cancer (NSCLC) by Identifying Clinically Relevant Biomarkers. It Will Also Develop Predictive Models Using De-identified Genomic Data to Assess Tumor Recurrence, Metastasis Risks, and Patient Responses to Both Standard Treatments and Off-label Drugs. Additionally, the Catos-ai Will Simulate Nanoparticle-based Drug Delivery Methods to Optimize Administration Strategies for New and Repurposed Therapies. the Project Further Includes the Development of a Cloud-based Clinical Software Platform With Robust Data Security, Privacy Protection, and Tiered Access for Users, Ensuring Its Usability in Real-world Clinical and Research Settings. This Sbir Phase Ii Effort Will Advance Catos-ai Into a Comprehensive Ai-powered Platform, Accelerating Drug Discovery, Improving Cancer Treatment Outcomes, and Enhancing Accessibility to Precision Medicine Solutions. This Award Reflects NSF'S Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Not Planned for This Award.
Committed
$1.2 Million
Paid out
$618.3K
50%
Committed, not yet paid
$618.3K
50%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.